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Behcet’s disease is a chronic multi-system disorder of unknown etiology with protean manifestations. Venous
thromboembolism is more common than arterial thrombosis, with deep vein thrombosis being the most frequent.
Endothelial dysfunction resulting from vascular inflammation is considered to be an important factor of thrombosis,
although the endothelial injury itself cannot completely explain the hypercoagulable state of the disease because
other vasculitis syndromes do not increase the risk of thrombosis. The aim of this study is to evaluate the
prevalence of activated protein C resistance (APC-R) in Egyptian patients with Behcet’s disease. Also, to detect
hyperhomocysteinemia in selected cases (with vascular complications) to assess their relationship with
thromboembolic complications. The APC resistance ratio mean in the group of patients with vascular involvement
was 2.6 ± 0.8 which was less than the group with no vascular involvement 2.8 ± 0.6, with non- significant P-value
(0.5). There was more incidence of ocular lesions in the group of patients with high homocysteine level than the
group of patients with normal homocytsteine level with significant P-value (0.08).Introduction
Behcet’s disease (BD), initially described by Hulusi
Behcet in 1937, is a chronic multi-system disorder of
unknown etiology with protean manifestations. The dis-
ease is clinically characterized by recurrent aphthous
oral ulcers, genital ulcers, ocular inflammation, and skin
lesions. It involves a variety of organs including joints,
the gastrointestinal tract, the central nervous system,
and the vascular system. The main histopathology of BD
is vasculitis, and neutrophilic or monocytic vascular
inflammation can involve large, medium or small vessels.
Thrombotic complications have been reported in ap-
proximately 10-40% of BD patients [1].
Venous thromboembolism (VTE) is more common than
arterial thrombosis, with deep vein thrombosis being the
most frequent [2]. Endothelial dysfunction resulting from
vascular inflammation is considered to be an important
factor of thrombosis, although the endothelial injury itself
cannot completely explain the hypercoagulable state of the
disease because other vasculitis syndromes do not increase
the risk of thrombosis [3].
Other alterations, such as deficiencies of protein C,
protein S and anti thrombin (AT), or the presence of
antiphospholipid antibodies and factor V Leiden and* Correspondence: edreesa@umkc.edu
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Although some studies found an association between
these abnormalities and thrombosis in Behcet’s disease
[4-8], many other studies did not find any of these ab-
normalities to be associated with Behcet’s disease [9,10].
Some studies have shown that hyperhomocysteinemia
might be assumed to be an independent and correctable
risk factor for thrombosis in BD. The association be-
tween homocysteine levels and endothelial dysfunction
has been shown in patients with BD [11,12].
The aim of this study is to evaluate the prevalence
of activated protein C resistance (APC-R) in Egyptian
patients with Behcet’s disease. Also, to detect hyperho-
mocysteinemia in selected cases (with vascular complica-
tions) to assess their relationship with thromboembolic
complications.Patient and methods
The study included thirty two patients with Behcet’s dis-
ease. Patients were seen in the outpatient clinic at Cairo
University Hospital. All patients fulfilled the Inter-
national Study Group Criteria for diagnosis of Behcet’s
Disease (International Study Group Criteria, 1990) [13].
This necessitates the presence of:
Recurrent oral ulcers observed by physician or patient,
which recurred at least three times in one 12-month
period, plus two of:entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Clinical characteristics of the study subjects
Clinical feature N %
Oral ulcers 32 100
Genital ulcers 30 93.8
Ocular lesions 15 46.9
Vascular involvement 17 53.1
Pathergy reaction 11 34.4
Skin lesions 13 40.6
Cardiac involvement 6 18.8
Pulmonary involvement 10 31.3
CNS involvement 6 18.8
Joint involvement 21 65.6
Gastrointestinal involvement 7 21.9
Low APC r. ratio 6 18.8
CNS Central Nervous System.
Table 2 Comparison between the clinical characteristics
of patients with low and normal ratio of APC resistance
ratio
Clinical feature Low ratio N = 6 Low ratio N = 26 P-value
N % N %
Genital ulcers 6 100 24 92.4 0.7
Ocular lesions 1 16.7 14 53.8 0.2
Vascular involvement 5 83.3 12 46.2 0.1
Pathergy reaction 3 50 8 30.8 0.3
Skin lesions 1 16.7 12 46.2 0.2
Cardiac involvement 2 33.3 4 15.4 0.3
Pulmonary involvement 3 50 7 26.9 0.3
CNS involvement 0 0 6 23.1 0.3
Joint involvement 4 66.7 17 65.4 0.7
GI involvement 2 33.3 5 19.2 0.4
GI Gastrointestinal.
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physician or patient.
2 Eye lesions: Anterior uveitis, posterior uveitis, or
cells in vitreous on slit lamp examination, or retinal
vasculitis observed by ophthalmologist.
3 Skin lesions: Erythema nodosum, pseudofolliculitis,
or acneiform eruption observed by physician in
post-adolescent patients not on corticosteroids
treatment.
4 Positive Pathergy test read by physician at 24–48
hours.
The following patients were excluded from the study:
– Patients under heparin or anticoagulant therapy as
these medications affect the result of the test for the
APC-R. If the patient was on oral anticoagulant, he
should stop (after physician and patient consent) for
one week and normalization of prothrombin time.
– Patients with prolonged APTT
– Pregnant females
– Women on Contraceptive pills
– Patients have disease or drugs affecting coagulation
pathway
– Patients with renal impairment or under treatment
with methotrexate, phenytoin, carbamazepine or
nitrous oxide were excluded.
Thirty two normal healthy subjects served as control.
They have no history of thromboembolism, they did not
include pregnant females or women on contraceptive
pills.
All patients were subjected to the following:
– Full history and clinical examination.
– Standard laboratory investigations including
complete blood picture, liver and kidney function
tests.
– Electrocardiogram
– Duplex study for the arterial and /or venous system
in patients suspected to have thrombotic event
according to the site.
– Patients suspected to have thromboembolic
complications, were further investigated by CT
chest, ventilation-perfusion scan and
echocardiography
– Activated protein C resistance test by coagulation
assay for all patients and the control subjects.
– Total plasma homocysteine concentration was
measured in ten selected patients from the studied
group who had vascular complications.
The test for APC resistance (COATEST) provides an
APTT-based assay for semi quantitative determinationof the response towards human APC. The prolongation
of basal APT clotting time after addition of APC is
shorter in plasma from individuals with APC resistance
than from individuals with normal response to APC.
Plasma is incubated with the APTT reagent for standard
period of time. Coagulation is triggered by the addition
of CaCl2 in the absence and presence of APC and the
time for clot formation is recorded.
Homocysteine was measured by ELISA using Abbott
AXSYM system. The normal range in females is
3.36 – 20.44 μmol/L, in males is 5.9- 16.0 μmol/L.
Statistical Package for Social Science (SPSS) program
version 9.0 was used for analysis of data. Data was
summarized as mean, SD. T test was done for analysis
of quantitative data and Non parametric test (Mann
Whitney U) was used for analysis of two independent






1 LL DVT 16 Superficial
thrombophlebitis
3 DVT (LL, IVC,
subclavian)
17 LL DVT, IVC thrombosis,
renal vein thrombosis
6 LL DVT, Budd Chiaria 22 Pulmonary artery
aneurysm






10 LL DVT, superior
sagittal sinus
thrombosis
29 LL and UL DVT
11 LL DVT 30 LL DVT, aortic aneurysm
12 LL DVT, internal jugular
vein thrombosis




DVT Deep Venous Thrombosis.
UL Upper Limb.
Table 4 Comparison between the clinical characteristics
patients normal and high homocysteine level





N % N %
Ocular lesions 1 14.3 2 66.6 0.08
Pathergy reaction 1 14.3 0 0 0.7
Skin lesions 3 42.9 1 33.3 0.7
Cardiac involvement 2 28.6 2 66.7 0.3
Pulmonary Involvement 4 57.1 1 33.3 0.5
CNS involvement 2 28.6 1 33.3 0.7
Joint involvement 5 71.4 1 33.3 0.3
GI involvement 3 42.9 0 0 0.3
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Chi square was used for analysis of qualitative data.
The study was approved by the institution review
board of Faculty of Medicine, Cairo University, Egypt
and all patients and control subjects signed an informed
consent.
Results
The study included 32 patients with Behcet’s and 32
healthy control persons, 24 patients were males (75%)
and 8 patients were females (25%).
The test for activated protein C resistance is considered
positive if the ratio ≤ 2. The test was positive in 6 patients
(18.8%). The test was positive in 2 control persons (6%).
There was non- significant difference in the number of
positive test between the two groups, P-value (0.2).
The age of the patients included in the study ranged
from 20 to 60 years with a mean 34.8 ± 9.2 years. Duration
of the disease ranged from 1 to 24 years with a mean
5.6 ± years. The clinical characteristics of the study patients
are summarized in Table 1. The comparison between the
clinical characteristics patients with low and normal ratio
of APC resistance ratio is summarized in Table 2.
Vascular involvement was detected in 17 patients
(53.1%) with the following details, the details of vascular
involvement is summarized in Table 3.
Activated protein C (APC) resistance ratio was done
for all patients. Minimum level was 1.4; maximum level
was 3.9 with a mean 2.7 ± 0.7, while in the control group
the mean was 2.7 ± 0.6 with non-significant probability
value (0.9).
Plasma homocysteine level was measured in 10 se-
lected patients with vascular complications. The level
was ranging from 8.3 to 25.2 μmol/L with a mean level
14.5 ± 5.6 μmol/L. Three patients had elevated levels
(normal range in males 5.9-16 μmol/L and in females
3.36-20.4 μmol/L). The three patients with elevated
homocysteine level were males.
The APC resistance ratio mean in the group of pa-
tients with vascular involvement was 2.6 ± 0.8 which was
less than the group with no vascular involvement
2.8 ± 0.6, with non- significant P-value (0.9).
There were more incidences of ocular lesions in the
group of patients with high homocysteine level than the
group of patients with normal homocytsteine level with
significant P-value (0.08).
The comparison between the clinical characteristics
patients normal and high homocysteine level is summa-
rized in Table 4.
Discussion
Various mechanisms can contribute to the vascular com-
plications in BD. Although a nonspecific vasculitis in-
volving small and large arteries and veins has beendescribed, the frequency of the thromboembolic phe-
nomena has led to the search for other factors that
might enhance intravascular clotting. Studies have inves-
tigated the prevalence and role of several factors with
procoagulant activity in the thromboembolic phenomena
in patients with BD. Most studies investigated these fac-
tors separately and yielded conflicting results [9].
This study showed a higher prevalence of activated
protein C resistance in patients with Behcet’s disease
(18.8%) than in the control group (6%) and was higher
in patients with vascular manifestations than those with-
out (29% versus 6.6% respectively) but without statistical
significance.
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resistance. This frequency is higher than that reported in
normal white populations (3 to 7%), and was higher than
our studied healthy control (6%). There was no significant
difference in the mean APC resistance ratio in our patients
and the control group (2.7 ± 0.7 versus 2.7 ± 0.6).
When we compared between the group with vascular
complications, the group without and the control group as
regard APC resistance, we didn’t find significant differ-
ence, however the mean in first group is lower than the
other groups. (2.6 ± 0.8, 2.8 ± 0.6, 2.7 ± 0.6 respectively).
Also, we observed that the prevalence of pathergy re-
action, cardiac, lung, and GI involvement were higher in
the group of APC resistance but again without statistical
significance.
Several studies evaluated factor V Leiden or APC resist-
ance as a potential risk factor for vascular complications
in BD in different Arab and non-Arab countries. The re-
sults were controversial Four studies presented significant
association between factor V Leiden mutation (or acti-
vated protein C resistance) and vascular complications in
BD patients (Gul et al. [2], and Gurgey et al. [14] from
Turkey, Mammo et al. [15] from Saudi Arabia, Navarro
et al. [16] from Spain), while other studies reported that
there was no significant association ( Toydemir et al. [17]
from Turkey, Verity et al. [18] from Jordan, Silingardi
et al. [19] from Italy).
As many epidemiologic studies supported, mild hyper-
homocysteinemia was found to be a risk factor for both
venous and arterial thrombosis. Endothelial dysfunction
due to inflammation is considered to be an important
factor of thrombosis in BD. Homocysteine is reported to
enhance endothelial-leukocyte interaction. Some studies
have shown that hyperhomocysteinemia might act as in-
dependent and correctable risk factor for thrombosis in
BD. Moreover, the association between homocysteine
levels and endothelial dysfunction has been shown in pa-
tients with BD [11].
In our study, we measured plasma homocysteine level
in 10 selected patients with vascular complications after
exclusion of disease or drugs affecting homocysteine
levels. We detected elevated levels in 3 patients (33.3%).
Evaluation of association between specific individual
clinical manifestations and hyperhomocysteinemia in
our study revealed higher prevalence in patients with
ocular and cardiac lesions.
There are several studies that evaluated hyperhomo-
cysteinemia in BD patients and their results were
conflicting. Aksu et al. [20], detected hyperhomo-
cysteinemia in BD patients with a history of thrombosis.
The significance of hyperhomocysteinemia in ocular
behcet’s was evaluated by Okka et al. [21]; they sug-
gested that hyperhomocysteinemia may play a role in
ocular involvement of BD.In conclusion, This study detected a higher prevalence
of activated protein C resistance in patients with Behcet’s
disease (18.8%) than the control (6%), and was higher in
patients with vascular manifestations than those without
(29% versus 6.6% respectively) but without statistical sig-
nificance. Although there was more incidence of positive
test for APC resistance in our patients we could not de-
tect statistically significant difference, the number of the
patients could be a limiting factor and further studies
with higher number of patients are required.
Homocysteine is a risk factor for thromboembolism in
BD (30% had hyperhomocysteinemia). Hyperhomo-
cysteinemia is correlated to ocular lesions, but studies
with large number of patients will be required to give
strong evidence.
The data about hypercoagulablity in BD could have
therapeutic implication in the management of deep vein
thrombosis and arterial thrombosis in patients with BD.
The current recommendations does not suggest the use
of anticoagulation for the vascular lesions of BD and
suggest the use of immunosuppressive medications only
based on the theory that the primary pathology leading
to venous thrombosis in BD is the inflammation of ves-
sel wall [22].
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